Search

Your search keyword '"Badawy, Sherif M."' showing total 6 results
Start Over Author "Badawy, Sherif M." Search Limiters Peer Reviewed Publication Year Range Last 3 years Journal british journal of haematology
6 results on '"Badawy, Sherif M."'

1. Mental health, pain and likelihood of opioid misuse among adults with sickle cell disease

Author

Jonassaint, Charles R., primary, Parchuri, Ektha, additional, O'Brien, Julia A., additional, Lalama, Christina M., additional, Lin, Jonathan, additional, Badawy, Sherif M., additional, Hamm, Megan E., additional, Stinson, Jennifer, additional, Lalloo, Chitra, additional, Carroll, C. Patrick, additional, Saraf, Santosh L., additional, Gordeuk, Victor R., additional, Cronin, Robert, additional, Shah, Nirmish, additional, Lanzkron, Sophie M., additional, Liles, Darla, additional, Trimnell, Cassandra, additional, Bailey, Lakiea, additional, Lawrence, Raymona H., additional, and Abebe, Kaleab Z., additional

Published
2024
Full Text
View/download PDF

2. Provider prescription of hydroxyurea in youth and adults with sickle cell disease: A review of prescription barriers and facilitators

Author

Pizzo, Alex, primary, Porter, Jerlym S., additional, Carroll, Yvonne, additional, Burcheri, Adam, additional, Smeltzer, Matthew P., additional, Beestrum, Molly, additional, Nwosu, Chinonyelum, additional, Badawy, Sherif M., additional, Hankins, Jane S., additional, Klesges, Lisa M., additional, and Alberts, Nicole M., additional

Published
2023
Full Text
View/download PDF

3. Does recipient body mass index inform donor selection for allogeneic haematopoietic cell transplantation?

Author

Abou‐Ismail, Mouhamed Yazan, primary, Fraser, Raphael, additional, Allbee‐Johnson, Mariam, additional, Metheny, Leland, additional, Ravi, Gayathri, additional, Ahn, Kwang Woo, additional, Bhatt, Neel S., additional, Lazarus, Hillard M., additional, Lima, Marcos, additional, El Jurdy, Najla, additional, Hematti, Peiman, additional, Beitinjaneh, Amer M., additional, Nishihori, Taiga, additional, Badawy, Sherif M., additional, Sharma, Akshay, additional, Pasquini, Marcelo C., additional, Savani, Bipin N., additional, Sorror, Mohamed L., additional, Stadtmauer, Edward A., additional, and Chhabra, Saurabh, additional

Published
2022
Full Text
View/download PDF

4. The safety and acceptability of twice‐daily deferiprone for transfusional iron overload: A multicentre, open‐label, phase 2 study

Author

Badawy, Sherif M., primary, Kattamis, Antonis, additional, Ezzat, Hatoon, additional, Deschamps, Benoît, additional, Sicard, Eric, additional, Fradette, Caroline, additional, Zhao, Feng, additional, Tricta, Fernando, additional, Chung Tsang, Yu, additional, Sheth, Sujit, additional, and Piga, Antonio, additional

Published
2021
Full Text
View/download PDF

5. Concordance with comprehensive iron assessment, hepatitis A vaccination, and hepatitis B vaccination recommendations among patients with sickle cell disease and thalassaemia receiving chronic transfusions: an analysis from the Centers for Disease Control haemoglobinopathy blood safety project

Author

Badawy, Sherif M., primary, Payne, Amanda B., additional, Hulihan, Mary M., additional, Coates, Thomas D., additional, Majumdar, Suvankar, additional, Smith, Dominic, additional, and Thompson, Alexis A., additional

Published
2021
Full Text
View/download PDF

6. The safety and acceptability of twice‐daily deferiprone for transfusional iron overload: A multicentre, open‐label, phase 2 study.

Author

Badawy, Sherif M., Kattamis, Antonis, Ezzat, Hatoon, Deschamps, Benoît, Sicard, Eric, Fradette, Caroline, Zhao, Feng, Tricta, Fernando, Chung Tsang, Yu, Sheth, Sujit, and Piga, Antonio

Subjects
*IRON overload, *RENAL colic
Abstract

Given that appropriate long-term iron chelation is essential in the treatment of transfusion-dependent anaemias,14,15 deferiprone b.i.d. has the potential to improve treatment adherence and health outcomes in patients with transfusional iron overload. Twenty-seven patients had a primary diagnosis of thalassaemia major, one patient had -thalassaemia/haemoglobin H disease and one patient had sickle -thalassaemia. Fourteen patients reported mild AEs, 13 patients reported moderate AEs and one patient reported a severe AE. Lifelong iron chelation therapy is critical for patients with transfusion-dependent anaemias, and full adherence to therapy is essential to optimise long-term patient outcomes.1,2 Deferiprone is an oral iron chelator with high efficiency in binding and removing excess intracellular and extracellular iron.3,4 Owing to its elimination half-life of approximately 2 h, deferiprone is administered three times daily (t.i.d.) to promote longer extent of exposure and better control of labile iron.5-7 Clinical trial data show adherence rates with deferiprone t.i.d. from 79% to 98%8,9; however, real-world adherence is generally lower than in clinical trials, as the t.i.d. regimen may be inconvenient and the midday dose may often be missed.10-12 The United States Food and Drug Administration recently approved a twice-a-day modified-release formulation of deferiprone (Ferriprox TAD 1000 mg tablet; manufactured by Apotex Inc., Toronto, Ontario, Canada) for the treatment of patients with transfusional iron overload due to thalassaemia syndromes, sickle cell disease or other anaemias.13 In single-dose and multiple-dose pharmacokinetic studies of deferiprone in healthy volunteers (Tables S1 and S2), we found that the twice-daily (b.i.d.) formulation had equivalent 24-h drug exposure to the original immediate-release tablet administered t.i.d. (Figure S1), and exposure was not affected by administration with food (Table S3). [Extracted from the article]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results